OncoSil clears key quality hurdle for Sydney manufacturing facility
OncoSil Medical has moved closer to local production after contract manufacturer Cyclotek secured ISO 13485 certification for its quality management system. Production at the Macquarie Park facility remains targeted for the end of 2Q FY27, subject to further regulatory approval.
- Cyclotek receives ISO 13485 medical-device quality certification
- Macquarie Park site still requires Notified Body approval
- Production targeted by the end of 2Q FY27
- Facility designed for higher capacity and less than 5% capital intensity at full capacity
Cyclotek certification advances Sydney production plans
OncoSil Medical Limited (ASX:OSL) has cleared an important quality milestone for its planned Sydney manufacturing operation, with contract manufacturer Cyclotek receiving ISO 13485 certification. The internationally recognised standard covers quality management systems used in the design, production and manufacture of medical devices.
The certification does not yet authorise production of the OncoSil device at Macquarie Park. OncoSil’s next regulatory step is to add the Sydney site as a critical subcontractor to its existing Notified Body certification, allowing the Notified Body to add Cyclotek to the company’s current certificate.
OncoSil is aiming to complete that process and commence production by the end of 2Q FY27, but the target remains conditional on regulatory review and approval. The announcement does not provide a confirmed production date, expected output or revenue contribution.
Facility built for capacity and supply-chain control
Management says the Macquarie Park facility is intended to support OncoSil’s global commercial activities with a scalable production platform. Its model combines Cyclotek’s existing infrastructure with OncoSil-owned equipment and the company’s proprietary manufacturing process.
Once operational, the facility is expected to provide greater control over product quality and manufacturing capability, while strengthening supply-chain resilience. OncoSil also says the site should support significantly higher annual production capacity with capital intensity of less than 5% at full capacity, although it has not quantified the capacity or the expected effect on gross margins.
CEO and managing director Nigel Lange said the company’s focus now shifts to adding Macquarie Park to its existing certification, describing the site as part of a scalable and capital-efficient manufacturing platform. The next meaningful test is therefore not the quality-system milestone itself, but whether the remaining Notified Body process is completed in time to support production by the stated target.
Bottom Line?
The quality hurdle is cleared, but Macquarie Park remains a regulatory project rather than an operating production site until the Notified Body approves the addition and manufacturing begins.
Questions in the middle?
- Can OncoSil complete the Notified Body approval process by the end of 2Q FY27?
- What annual production capacity will the Macquarie Park facility deliver once fully operational?
- How much of the anticipated manufacturing-efficiency and gross-margin benefit will appear in reported results?
